



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: F. Haviv, et al.

Serial No.: 09/718,591

Filed: November 22, 2000

For: PEPTIDES HAVING
ANTIANGIOGENIC ACTIVITY

Case No.: 6633.US.O2

Group Art Unit: 1653

Examiner: David Lukton

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to:

Commissioner for Patents
Washington, D.C. 20231

Date of Deposit: February 12, 2003

Jenny Rizzotto

Date

RESPONSE TO RESTRICTION REQUIREMENT

Director of Patents and Trademarks
Washington, D.C. 20231

RECEIVED

FEB 21 2003

TECH CENTER 1600/2900

Dear Sir:

This communication is responsive to the Restriction Requirement dated September 27, 2002, having a period of response through February 27, 2003, pursuant to a four (4) month extension of time under 37 C.F.R. §§ 1.136(a).

The Examiner has divided the claims into G1 and G2 subgenera.

Applicants hereby elect invention "1." in which G2 is Xaa₁ in which Xaa₁ can be whatever the claims permit, provided that G1 is excluded. Applicants also hereby elect Example 1 as a species for search purposes. This example is found on pages 32-34 of the specification and is recited generically in claims 1-25 and 27 and as a species in claim 30. Applicants respectfully submit that EXAMPLE 1 is not recited in claim 29.

For the Examiner's convenience, the name of the compound is shown below.

EXAMPLE 1

N-Ac-Sar-Gly-Lys(Ac)-D-Leu-Thr-Nva-Ile-Arg-Pro-NHEt

BEST AVAILABLE COPY

This species is the compound of claim 1, in which Xaa₁ is R¹(CH₂)_n-C(O)-, in which R¹ is C₁-alkyl and n is zero; Xaa₂ is sarcosyl; Xaa₃ is glycyl; Xaa₄ is lysyl(N-eplison-acetyl); Xaa₅ is D-leucyl; Xaa₆ is threonyl; Xaa₇ is norvalyl; Xaa₈ is isoleucyl; Xaa₉ is arginyl; Xaa₁₀ is prolyl; and Xaa₁₁ is -NH-(CH₂)_s-CH(R³)(R⁴), in which s is one and R³ and R⁴ are hydrogen.

Amendment of the claims to reflect the election is deferred until examination on the merits.



23492

ABBOTT LABORATORIES

Telephone: (847) 937-3810

Facsimile: (847) 938-2623

Respectfully submitted,
F. Haviv et al.

B. Gregory Donner
Registration No. 34,580
Agent for Applicants

BEST AVAILABLE COPY